Mettler-Toledo International Inc. (MTD) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (59.4% gross margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Mettler-Toledo International Inc. (NYSE: MTD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1,674.81 (-2.55% 1D, market cap $33.56B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, MTD ranks #20 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), MTD carries a Roarable B+ (78/100 RQD), trailing P/E of 39.6x, gross margin of 59.4%, and ROIC of 30.4%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and A (Agilent Technologies Inc.) posts a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).
Per MTD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001037646), Mettler-Toledo International Inc. generated $4.03B in revenue (+4.0% YoY), $869.2M in net income, and $848.6M in free cash flow against $3.71B in total assets and $2.09B in total debt. Key quantitative strengths: Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±4.9% realized swing band)
SEC XBRL FY 2025 (10-K): 21.1% FCF Margin ($848.6M FCF) & 59.4% Gross Margin
Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
Even with a 78/100 (B+) score, MTD faces multiple-compression risk if 39.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 40x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1,512.37) or 200D SMA ($1,341.24) invalidates the momentum regime and cuts Target Base ($1,825.54) toward Bear Floor ($1,373.34).
Mettler-Toledo International Inc. (MTD) dropped -2.55% to $1674.81, trading at 92% of its 52-week range ($1023.05 – $1728.66). High-quality cash engine (59.4% gross margin, 30% return on capital) with steady institutional support.
Seeking Alpha report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Zacks highlights MPC, AMGN and CVX as standout performers, with strong returns across its stock recommendations and model portfolios despite market volatility.
COLUMBUS, Ohio, October 30, 2026--Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the UBS Global Healthcare Conference on Wednesday, November 11 at 8:45 a.m. Eastern Standard Time, and at
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MTD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MTD. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Mettler-Toledo International Inc. (MTD) ranks #20 by composite RQD confidence (78/100, grade B+) and #53 by equity capitalization ($33.56B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MTD
ACTIVE
Mettler-Toledo International Inc. | B+ | 78/100 | 39.6x | 59.4% | 30.4% | -2.55% | $33.56B | Benchmark Subject |
| WAT Waters Corporation | B | 72/100 | 73.4x | 59.3% | 16.8% | -3.61% | $45.46B | /wat-vs-mtd → |
| A Agilent Technologies Inc. | B | 72/100 | 39.2x | 52.4% | 15.3% | -3.47% | $49.30B | /a-vs-mtd → |
| RVTY Revvity Inc. | C | 65/100 | 76.7x | — | 3.1% | -5.30% | $17.52B | /rvty-vs-mtd → |
| AVTR Avantor Inc. | D+ | 56/100 | — | 32.7% | -2.1% | -3.78% | $10.88B | /avtr-vs-mtd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mettler-Toledo International Inc. (MTD) reported GAAP revenue of $4.03B (+4.0% vs. FY2024 revenue of $3.87B , and +6.3% cumulative change since FY2023) , GAAP net income of $869.2M, operating cash flow of $955.8M, and free cash flow of $848.6M (-1.8% YoY). On the balance sheet, MTD closed FY2025 with $3.71B in total assets against $2.09B in total debt (Altman Z-Score: 11.09, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.03B | $869.2M | $955.8M | $848.6M | $3.71B | $2.09B |
| FY2024 (FY) | 2024-12-31 | $3.87B | $863.1M | $968.3M | $864.4M | $3.24B | $1.83B |
| FY2023 (FY) | 2023-12-31 | $3.79B | $788.8M | $965.9M | $795.4M | $18.94B | $4.43B |
As of 2026-11-03, Mettler-Toledo International Inc. (NYSE: MTD) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1,674.81 (-2.55% 1D, market cap $33.56B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, MTD ranks #20 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), MTD carries a Roarable B+ (78/100 RQD), trailing P/E of 39.6x, gross margin of 59.4%, and ROIC of 30.4%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and A (Agilent Technologies Inc.) posts a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).
Per MTD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001037646), Mettler-Toledo International Inc. generated $4.03B in revenue (+4.0% YoY), $869.2M in net income, and $848.6M in free cash flow against $3.71B in total assets and $2.09B in total debt. Key quantitative strengths: Strong cash generator (59.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 40x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
MTD last traded at $1,674.81 (-2.55% on volume of 189,705 shares), positioning the stock +10.74% above its 50-day simple moving average ($1,512.37) and +24.87% above its 200-day simple moving average ($1,341.24). Across its 52-week range of $1,023.05 to $1,728.66, MTD sits at the 92.4% percentile with a 14-day RSI of 60.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($1,592.74 to $1,756.88).
Mettler-Toledo International Inc. (MTD) earns a live Roarable RQD composite score of 78/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $1,674.81 (-2.55% 1D, market capitalization $33.56B).
Mettler-Toledo International Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry,. The company generated revenue of $4.03B in FY 2025, indicating a sizable operating business.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mettler-Toledo International Inc. (MTD) reported $4.03B in annual revenue (up from $3.87B in FY2024, +4.0% YoY) and $869.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.79B revenue, $788.8M net income) through FY2025, MTD scaled operating cash flow to $955.8M and free cash flow to $848.6M, backed by $3.71B in total assets against $2.09B in total debt.
Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), MTD carries a macro regime beta of 0.87 and gross margin of 59.4%.
Real-time company headlines, analyst actions, and sector developments for Mettler-Toledo International Inc. (MTD) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Mettler-Toledo International Inc. (MTD) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Mettler-Toledo International Inc. (MTD). Returns on capital are exceptional, with ROIC of 30.4% and an Altman Z-Score of 11.09 signaling strong quality and financial health.. With an RQD score of 78/100 (B+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1808.79.
@MacroHawk_NYC Agree on the RQD 78/100 quality, though with 0.87 beta I'm scaling in with half-size at $1674.81 and keeping dry powder in case we test $1557.57.
The stock trades at a P/E (TTM) of 39.6 and an FCF yield of only 2.46%, leaving limited room for error if growth slows.. Look at the math on MTD: paying 39.6x trailing P/E for 30.4% ROIC and 26.3% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $1473.83 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).